Beth Faiman PhD

Passionate about the diagnosis, management & care of patients with #multiplemyeloma #amyloidosis and #bloodcancer. And my family❤️. Tweets are my own.

[Beth Faiman PhD @Bethfaiman]

@Rea_Booker @IMFmyeloma Yes!!! You would be perfect / I will nominate you!

[Beth Faiman PhD @Bethfaiman]

Honored to serve the @IMFmyeloma as a founding member of the #nurse #leadership #board since 2006! This year, the board was expanded to include experts from Singapore and Switzerland. I am in awe of the board’s accomplishments over the years, and planned projects for 2027!! @domenica76 @marymyeloma @TiffanyRic48662 @MMKingT @IMFnurseMyeloma @LisaHwa2

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium #mmsm @BloodCancerJnl @utswcancer @AimazAfrough @ldandersonjr

➡️ https://t.co/ZnDqCuvdBR

[Vincent Rajkumar @VincentRK]

3. The ECOG trial that showed that lowering the dose of dexamethasone in myeloma saves lives. @TheLancetOncol 2010

Randomized trial that helped my career the most. Design proposed by a patient advocate! We didn’t realize the 10% mortality in the first year following diagnosis that occurred in newly diagnosed myeloma due to Dex related toxicity until this trial. The trial was done in a narrow population with doublet regimen. But the results were compelling and welcomed by patients and physicians alike that it became standard across the board with all regimens and all settings. @Rfonsi1

These type of randomized trials are only possible through @theNCI funded cooperative groups: @eaonc @SWOG @ALLIANCE_org

Leadership of these trials requires investment of years participating in the group activities and perseverance. Also skill and effort because every word of the protocol and paper you have to write.

[Vincent Rajkumar @VincentRK]

Final one is a bonus. Not authored by me. It’s a gift from @TheLancet 2011

Totally mind boggling that most of us will be happy to have a small paper in @TheLancet — but to have The Lancet do a paper on you is still unbelievable for me even after all these 15 years!

[Vincent Rajkumar @VincentRK]

Just when medicine has become incredibly complex due to dramatic scientific advances, the need for more expertise and individualization for best outcomes, and when patients want physicians who are competent, empathetic, and accessible…

We are in the midst of continued physician burnout, loss of autonomy, and micromanagement. Physicians are leaving the profession early or cutting down work hours (FTE) to cope. Patients with complex problems want the best expert for their care but experts are leaving clinical jobs for non clinical ones.

The solution will only come from visionary leaders who put the welfare of patients first. From physician Leaders who connect with their colleagues and find out what the problems are and genuinely try to help solve it. From realizing that a broken healthcare delivery system with big physician shortages particularly in fields like oncology where the choice of a wrong therapeutic strategy can have massive consequences affects everyone eventually.

I’m not seeing much of the kind of leadership that’s needed, only a lot of fancy words and sentences that I really don’t know the meaning of.

[@MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher]

Congratulations @SagarLonialMD Well deserved honor. See you in Glasgow

[Joshua Richter, MD, FACP @JoshuaRichterMD]

The lifeblood of the myeloma community !!!

[Beth Faiman PhD @Bethfaiman]

@JoshuaRichterMD ♥️♥️♥️

[Vincent Rajkumar @VincentRK]

4. Daratumumab is effective in high risk smoldering multiple myeloma. (AQUILA). @NEJM 2024

Randomized trial that showed early intervention works. International effort that to the first approved therapy for high risk smoldering myeloma. Changed paradigm. 10 years from trial concept to publication. But over 20 years from the time of my first trial in SMM. It takes time and there are no shortcuts.

This type of trial requires a track record in the field on the particular topic. Leading many natural history studies, phase IIs and a phase III in SMM before helped. Patience and time. It also needs a conviction in the hypothesis: in this case that early intervention works.

[Beth Faiman PhD @Bethfaiman]

Diane Moran kicking off the 20th #Nurseleadership board meeting! @IMFmyeloma @domenica76 @TiffanyRic48662 @IMFnurseMyeloma @marymyeloma @MMKingT

[Murali Janakiram @JanakiramMurali]

Dear Dr. Rajkumar- This is very inspirational, and thx for all your /team’s contributions to the field. You are a role model for many of us. For all faculty interested in MM attending the co-operative group calls @eaonc @SWOG @ALLIANCE_org listening to leaders and interacting with the group @VincentRK @myelomaMD @nsc_natalie @DoctorAKrishnan @szusmani @myelomaMD @SagarLonialMD paves the way for good research.

[Oncology Brothers @OncBrothers]

Treatment Algorithm discussion on Early Relapse/Refractory #MultipleMyeloma w/ @myelomaMD

✅ CARTs
✅ BsAbs
✅ Triplets
✅ Awaited options

Full 🗣️:
⭐️ https://t.co/m9yYhf0tgH
⭐️ Also on “Oncology Brothers” podcast

#OncTwitter #HemeTwitter @OncUpdates @OncoAlert #mmsm

[Urvi Shah @UrviShahMD]

Excellent points for ASH abstracts that are often overlooked @End_myeloma #ASH26

[Paul H, PharmD, RPH @phsiao4]

@OncBrothers @VincentRK @myelomaMD @RenoHemonc @BijoyTelivala @SuyogCancer @GKaurMD @RahulBanerjeeMD @Myeloma_Doc @Bethfaiman @MyelomaTeacher Lenalidomide was approved in December 2005. 20 yeas have gone by and we are just starting to learn how to use it appropriately vs indefinitely. ENDURANCE trial will be used as the benchmark especially when dealing with novel ADCs, Bispecific Antibodies.

[Oncology Brothers @OncBrothers]

Based off #ENDURANCE trial, Lenalidomide is now for 2yrs maintenance (instead of indefinite) for standard risk #MultipleMyeloma (75-80% of myeloma can fall in this category). Indefinite maintenance did NOT improve OS when compared to 2yrs therapy!

#HemeTwitter #OncTwitter

[Beth Faiman PhD @Bethfaiman]

Thank you for all who joined! @i3health @RahulBanerjeeMD

[i3 Health @i3health]

Tonight’s the night! Join leading experts Rahul Banerjee, MD, Beth Faiman, PhD, and Ashley Chen, PharmD, at 7:00 PM EST to elevate your case-based NDMM strategies and claim credit. Register HERE: https://t.co/QrsdNM3nGU

@RahulBanerjeeMD | @UW
@BethFaiman | @ClevelandClinic

[Paul H, PharmD, RPH @phsiao4]

Bortezomib (Velcade) was first approved by the FDA in 2003. Finally 23 yrs later generic bortezomib available from at least 10 generic companies. The market price has dropped from $1600/vial to under $20/vial. A big fan of A/P rated generic injectables.

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: International Myeloma Working Group recommendations for diagnosis & management of solitary #plasmacytomas: https://t.co/lDJ4laJ5iR. #mmsm Note the 50% risk of progression to symptomatic myeloma within 5 years after initial definitive local radiotherapy.

[Saurabh Zanwar @ZanwarSaurabh]

👏👏👏 much needed study!!